Comparing ticagrelor to standard dual antiplatelet therapy after heart procedures
Official title: A Single-center, Randomized, 6-month, Non-inferiority Study to Compare the Safety and Efficacy of TICAgreLor mONotherapy Versus Dual Antiplatelet Therapy in Chronic Coronary Syndrome Patients Post Percutaneous Coronary IntErvention (TICALONE)
Run by Shiraz University of Medical Sciences · NCT06509893 · Data updated 2026-11-12
This study is testing if taking ticagrelor alone is better than the usual combination of aspirin and clopidogrel for heart patients after a procedure to see if it helps prevent serious heart problems.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Enrollment | 5400 (estimated) |
| Sponsor | Shiraz University of Medical Sciences Academic / other |
| Locations | 2 sites (Shiraz, Fars and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | December 1, 2025 |
| Study ends | May 1, 2026 |
| Registry record updated | May 21, 2025 |
| Trial ID | NCT06509893 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 20 years old undergoing PCI with a drug-eluting stent for chronic coronary syndrome.
✕Probably not a fit
Patients with contraindications to the study medications or those requiring anticoagulant therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the efficacy of ticagrelor monotherapy compared to standard dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in patients undergoing percutaneous coronary intervention (PCI) for chronic coronary syndrome. Patients will be randomly assigned to receive either ticagrelor or the conventional DAPT for six months following their procedure. The primary focus is to assess the occurrence of major adverse cardiovascular events (MACE) within this period. The study is conducted at a single center, with careful monitoring of patient outcomes through a registry.
Why it matters
Potential benefit: If successful, this study could provide a more effective antiplatelet therapy option for patients after PCI, potentially reducing the risk of major cardiovascular events.
How similar studies have gone: Previous studies have shown promising results with ticagrelor in similar patient populations, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome * The patient has provided written informed consent as approved by the ethics committee of the Shiraz University of Medical Sciences. Exclusion Criteria: * Contraindication to aspirin, clopidogrel, ticagrelor, or any other reason that study drug should not be administered (including hypersensitivity, moderate or severe liver disease, active bleeding, and major surgery within 30 days) * Atrial fibrillation or other indication for oral anticoagulant therapy. * Concomitant oral or IV therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices (cyclosporine, and quinidine), or strong CYP3A inducers ( rifampin, rifampicin, phenytoin, and carbamazepine) * Females of child-bearing age unless negative pregnancy test at screening and willing to use effective contraception for the duration of trial * Females who are breastfeeding at the time of enrolment. * Unsuccessful PCI or PCI without optimal stent placement; this decision is made by the supervising interventional cardiologist. * patients with anatomical SYNTAX score ≥23 prior to PCI * Patients with planned surgical intervention to treat any cardiac or non-cardiac condition. * Previous PCI in the last 6 months. * Current (same hospitalization) or previous (within 12 months) acute coronary syndrome. * History of definite stent thrombosis. * Concomitant cardiac valve disease requiring invasive therapy. * Acute heart failure. * Active myocarditis. * Cardiomyopathy. * Patient in hemodialysis. * History of stroke or transient ischemic cerebrovascular accident. * History of intracranial hemorrhage or other intracranial pathology associated with increased bleeding risk. * Hemoglobin \<10 g/dL * Peptic ulceration documented by endoscopy within the last 3 months unless healing proven by repeat endoscopy. * Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with ticagrelor. * Participation in another trial with an investigational drug or device. * Assessment that the subject is not likely to comply with the study procedures or have complete follow-up. * Known drug or alcohol dependence within the past 12 months as judged by the investigator.
Where it's running
-
Cardiology Ward Shiraz University of Medical Sciences
Shiraz, Fars, Iran Recruiting -
professor Kojuroi cardiology clinic
Shiraz, Iran Recruiting
Study contacts
- Study coordinator: javad UOM Kojuri, MD.MS
- Email: kojurij@yahoo.com
- Phone: 09171115083
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.